A bill for an act relating to a review of anti-obesity medications by the department of health and human services and the department of administrative services for purposes of the medical assistance program and health insurance plans for state employees.

SF 552 requires Iowa's Department of Health and Human Services (HHS) and Department of Administrative Services (DAS) to review anti-obesity medications - including GLP-1 agonists - for use in two specific programs: the state's medical assistance program (Medicaid) and health insurance plans for state employees. The review must assess medication effectiveness for weight loss, impact on related health conditions (comorbidities), potential cost savings, recommended eligibility, and short- and long-term coverage costs. HHS and DAS must submit a report to the legislature by January 5, 2026, detailing their findings, proposed eligibility rules, and cost analysis. This bill does not change current coverage but mandates a formal review to inform future policy decisions.